GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
V

Vitaspring Biomedical Co. VSBC · USD

N/A · US listing · 🇺🇸 United States

Compare

0.02

—

Close of 5 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Vitaspring Biomedical Co.

From its filings with the US Securities and Exchange Commission

SEC filings

Vitaspring Biomedical Co. is based in Riverside, California and is incorporated in Nevada. Its shares trade on OTC under the ticker VSBC. The SEC classifies its business as commercial physical & biological research. In the fiscal year to 31 January 2026, it reported revenue of $0 and a net loss of $415,368. At that date it held total assets of $14,676 and shareholders' equity of −$4.4m.

In its own words

VitaSpring Biomedical Co. Ltd. (“VitaSpring,” the “Company,” “we,” “us,” or “our”), formerly known as Shemn Corp., was incorporated in the State of Nevada on September 6, 2016. We are a development-stage biomedical company engaged in the research, development, and commercialization of products that promote wellness and a healthy lifestyle. We began operations in 2019 and underwent a change of ownership effective January 21, 2020, resulting in a new management team and strategic direction. In connection with this ownership change, we filed a Certificate of Amendment to our Articles of Incorporation to change our corporate name to VitaSpring Biomedical Co. Ltd., which became effective on April 21, 2020, following clearance by the Financial Industry Regulatory Authority (“FINRA”). Our fiscal year end is January 31.

We aim to advance the field of cellular and regenerative medicine through investment in research and development of stem cell–based applications and related biomedical innovations. Our strategic objectives include establishing advanced medical research and cell production centers meeting Good Tissue Practice (“GTP”) standards and developing high-quality stem cell preparations for use in regenerative therapies and potential future drug development.

Quoted from its 10-K, filed 17 Jun 2026. Read the filing on SEC.gov ↗

Company facts

Sector
N/A
Industry
N/A
Listed since
1 Oct 2019
Head office
5225 CANYON CREST DR., RIVERSIDE, CA, 92507
Incorporated in
NV
Classification
Services-Commercial Physical & Biological Research
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Dr. Ssu-Chuan LaiChairperson of the Board, Chief Executive Officer, Chief Financial Officer, Executive Director, since 2025

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.